Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$13.07
At close: May 29 EDT
$13.07
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Centessa Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CNTA | Benzinga
Centessa Pharmaceuticals PLC has a consensus price target of $22.46 based on the ratings of 15 analysts. The high is $38 issued by Piper Sandler on March 31, 2025. The low is $5 issued by Goldman Sachs on August 15, 2023. The 3 most-recent analyst ratings were released by Needham, Chardan Capital, and Piper Sandler on May 28, 2025, May 8, 2025, and March 31, 2025, respectively. With an average price target of $34.33 between Needham, Chardan Capital, and Piper Sandler, there's an implied 162.69% upside for Centessa Pharmaceuticals PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Chardan Capital
Piper Sandler
Guggenheim
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Centessa Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/28/2025 | Buy Now | 167.79% | Needham | Ami Fadia57% | → $35 | Initiates | → Buy | Get Alert |
| 05/08/2025 | Buy Now | 129.53% | Chardan Capital | Rudy Li34% | → $30 | Initiates | → Buy | Get Alert |
| 03/31/2025 | Buy Now | 190.74% | Piper Sandler | Biren Amin39% | → $38 | Initiates | → Overweight | Get Alert |
| 03/26/2025 | Buy Now | 114.23% | Guggenheim | Debjit Chattopadhyay53% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2025 | Buy Now | 106.58% | Morgan Stanley | Jeffrey Hung50% | $27 → $27 | Assumes | → Overweight | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay53% | — | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | — | TD Cowen | Stacy Ku20% | — | Initiates | → Buy | Get Alert |
| 11/15/2024 | Buy Now | 114.23% | Guggenheim | Debjit Chattopadhyay53% | $24 → $28 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 98.93% | Morgan Stanley | Jeffrey Hung50% | $11 → $26 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 09/19/2024 | Buy Now | 152.49% | B. Riley Securities | Mayank Mamtani71% | → $33 | Initiates | → Buy | Get Alert |
| 09/16/2024 | Buy Now | 167.79% | BMO Capital | Kostas Biliouris33% | $20 → $35 | Maintains | Outperform | Get Alert |
| 09/11/2024 | Buy Now | 83.63% | Guggenheim | Debjit Chattopadhyay53% | $20 → $24 | Maintains | Buy | Get Alert |
| 09/11/2024 | Buy Now | 45.37% | Jefferies | Kelly Shi42% | $13 → $19 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 53.02% | BMO Capital | Kostas Biliouris33% | $15 → $20 | Maintains | Outperform | Get Alert |
| 08/14/2024 | Buy Now | 7.12% | Oppenheimer | Francois Brisebois40% | $14 → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 07/18/2024 | Buy Now | 7.12% | Oppenheimer | Francois Brisebois40% | → $14 | Initiates | → Outperform | Get Alert |
| 06/21/2024 | Buy Now | -15.84% | Morgan Stanley | Matthew Harrison61% | $8 → $11 | Maintains | Equal-Weight | Get Alert |
| 04/01/2024 | Buy Now | 14.77% | BMO Capital | Kostas Biliouris33% | $15 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | -15.84% | Jefferies | Kelly Shi42% | $4 → $11 | Upgrade | Hold → Buy | Get Alert |
| 10/26/2023 | Buy Now | -38.79% | Morgan Stanley | Matthew Harrison61% | $4 → $8 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 08/15/2023 | Buy Now | -15.84% | SVB Securities | David Risinger72% | $6 → $11 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | -23.49% | Guggenheim | Debjit Chattopadhyay53% | $9 → $10 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | -61.74% | Goldman Sachs | Salveen Richter53% | $4.5 → $5 | Maintains | Neutral | Get Alert |
| 07/25/2023 | Buy Now | 14.77% | BMO Capital | Kostas Biliouris33% | $11 → $15 | Maintains | Outperform | Get Alert |
| 06/21/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat43% | — | Initiates | → Outperform | Get Alert |
| 06/12/2023 | Buy Now | -31.14% | Guggenheim | Debjit Chattopadhyay53% | → $9 | Initiates | → Buy | Get Alert |
| 05/15/2023 | Buy Now | -65.57% | Goldman Sachs | Salveen Richter53% | $4 → $4.5 | Maintains | Neutral | Get Alert |
| 03/17/2023 | Buy Now | -54.09% | SVB Leerink | David Risinger72% | → $6 | Initiates | → Outperform | Get Alert |
| 01/24/2023 | Buy Now | -69.4% | Morgan Stanley | Matthew Harrison61% | $5 → $4 | Maintains | Underweight | Get Alert |
| 08/12/2022 | Buy Now | -61.74% | Morgan Stanley | Matthew Harrison61% | $10 → $5 | Downgrade | Overweight → Underweight | Get Alert |
| 08/11/2022 | Buy Now | -15.84% | BMO Capital | Kostas Biliouris33% | $19 → $11 | Maintains | Outperform | Get Alert |
| 08/11/2022 | Buy Now | -69.4% | Goldman Sachs | Salveen Richter53% | $5 → $4 | Maintains | Neutral | Get Alert |
| 07/15/2022 | Buy Now | -23.49% | Morgan Stanley | Matthew Harrison61% | $15 → $10 | Maintains | Overweight | Get Alert |
| 06/17/2022 | Buy Now | 45.37% | BMO Capital | Kostas Biliouris33% | → $19 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Centessa Pharmaceuticals (CNTA) stock?
The latest price target for Centessa Pharmaceuticals (NASDAQ:CNTA) was reported by Needham on May 28, 2025. The analyst firm set a price target for $35.00 expecting CNTA to rise to within 12 months (a possible 167.79% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ:CNTA) was provided by Needham, and Centessa Pharmaceuticals initiated their buy rating.
When was the last upgrade for Centessa Pharmaceuticals (CNTA)?
The last upgrade for Centessa Pharmaceuticals PLC happened on September 19, 2024 when Morgan Stanley raised their price target to $26. Morgan Stanley previously had an equal-weight for Centessa Pharmaceuticals PLC.
When was the last downgrade for Centessa Pharmaceuticals (CNTA)?
The last downgrade for Centessa Pharmaceuticals PLC happened on August 12, 2022 when Morgan Stanley changed their price target from $10 to $5 for Centessa Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on May 28, 2025 so you should expect the next rating to be made available sometime around May 28, 2026.
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a initiated with a price target of $0.00 to $35.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $13.07, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
